About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Immuno-Oncology Assays Market Size, Share and Forecast to 2031

Immuno-Oncology Assays Market Size, Share & Trends Analysis Report By Product (Consumables, Software), By Technology (Immunoassay, PCR, NGS, Flow Cytometry, Others), By Indication (Colorectal Cancer, Lung Cancer, Melanoma, Bladder Cancer, Others), By Application (Clinical Diagnostics, Research) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI54479DR
Author : Debashree Bora

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Immuno-Oncology Assays Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    6. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Consumables
          1. By Value
        3. Software
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Immunoassay
          1. By Value
        3. PCR
          1. By Value
        4. NGS
          1. By Value
        5. Flow Cytometry
          1. By Value
        6. Others
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Colorectal Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Melanoma
          1. By Value
        5. Bladder Cancer
          1. By Value
        6. Others
          1. By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Clinical Diagnostics
          1. By Value
        3. Research
          1. By Value
    7. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    6. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Consumables
          1. By Value
        3. Software
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Immunoassay
          1. By Value
        3. PCR
          1. By Value
        4. NGS
          1. By Value
        5. Flow Cytometry
          1. By Value
        6. Others
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Colorectal Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Melanoma
          1. By Value
        5. Bladder Cancer
          1. By Value
        6. Others
          1. By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Clinical Diagnostics
          1. By Value
        3. Research
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    6. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Consumables
          1. By Value
        3. Software
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Immunoassay
          1. By Value
        3. PCR
          1. By Value
        4. NGS
          1. By Value
        5. Flow Cytometry
          1. By Value
        6. Others
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Colorectal Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Melanoma
          1. By Value
        5. Bladder Cancer
          1. By Value
        6. Others
          1. By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Clinical Diagnostics
          1. By Value
        3. Research
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    6. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Consumables
          1. By Value
        3. Software
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Immunoassay
          1. By Value
        3. PCR
          1. By Value
        4. NGS
          1. By Value
        5. Flow Cytometry
          1. By Value
        6. Others
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Colorectal Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Melanoma
          1. By Value
        5. Bladder Cancer
          1. By Value
        6. Others
          1. By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Clinical Diagnostics
          1. By Value
        3. Research
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Consumables
        1. By Value
      3. Software
        1. By Value
    3. By Technology
      1. Introduction
        1. Technology By Value
      2. Immunoassay
        1. By Value
      3. PCR
        1. By Value
      4. NGS
        1. By Value
      5. Flow Cytometry
        1. By Value
      6. Others
        1. By Value
    4. By Indication
      1. Introduction
        1. Indication By Value
      2. Colorectal Cancer
        1. By Value
      3. Lung Cancer
        1. By Value
      4. Melanoma
        1. By Value
      5. Bladder Cancer
        1. By Value
      6. Others
        1. By Value
    5. By Application
      1. Introduction
        1. Application By Value
      2. Clinical Diagnostics
        1. By Value
      3. Research
        1. By Value
    6. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Consumables
          1. By Value
        3. Software
          1. By Value
      2. By Technology
        1. Introduction
          1. Technology By Value
        2. Immunoassay
          1. By Value
        3. PCR
          1. By Value
        4. NGS
          1. By Value
        5. Flow Cytometry
          1. By Value
        6. Others
          1. By Value
      3. By Indication
        1. Introduction
          1. Indication By Value
        2. Colorectal Cancer
          1. By Value
        3. Lung Cancer
          1. By Value
        4. Melanoma
          1. By Value
        5. Bladder Cancer
          1. By Value
        6. Others
          1. By Value
      4. By Application
        1. Introduction
          1. Application By Value
        2. Clinical Diagnostics
          1. By Value
        3. Research
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Immuno-Oncology Assays Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Agilent Technologies
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. F. Hoffmann-La Roche
    3. HTG Molecular Diagnostics
    4. Illumina
    5. Merck
    6. NanoString Technologies
    7. PerkinElmer
    8. Qiagen
    9. Sartorius
    10. Thermo Fisher Scientific
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Straits Research - Access Portal
  • 📊 Preview Report Scope and Structure – Gain immediate visibility into key topics, market segments, and data frameworks covered.
  • 📥 Evaluate Strategic Insights – Access selected charts, statistics, and analyst-driven commentary derived from the final report deliverables.
Get Free Access


We are featured on :

www.straitsresearch.com
© Copyright . All rights Reserved.